Correlation of capecitabine-induced skin toxicity with treatment efficacy in patients with metastatic colorectal cancer: results from the German AIO KRK-0104 trial
Authors:
Open Access
- 12 July 2011
- journal article
- research article
- Published by Springer Nature in British Journal of Cancer
- Vol. 105 (2) , 206-211
Abstract
The AIO KRK-0104 randomised phase II trial investigated the efficacy and safety of two capecitabine-based regimens: combination of capecitabine and irinotecan (CAPIRI) plus cetuximab (CAPIRI-C) and combination of capecitabine with oxaliplatin (CAPOX) plus cetuximab (CAPOX-C) in the first-line treatment of metastatic colorectal cancer (mCRC). Treatment-related skin toxicity (ST) was evaluated separately for capecitabine and cetuximab. The present analysis investigates the correlation of capecitabine-attributed ST (Cape-ST) and parameters of treatment efficacy. Patients with mCRC were randomised to cetuximab (400 mg m−2, day 1, followed by 250 mg m−2 weekly) plus CAPIRI (irinotecan 200 mg m−2, day 1; capecitabine 800 mg m−2, twice daily, days 1–14, every 3 weeks), or cetuximab plus CAPOX (oxaliplatin 130 mg m−2, day 1; capecitabine 1000 mg m−2, twice daily, days 1–14, every 3 weeks). Of 185 recruited patients, 149 (CAPIRI-C, n=78; CAPOX-C, n=71) received study treatment beyond the first tumour assessment and were evaluable for efficacy. Capecitabine-attributed ST, predominantly hand–foot syndrome, was observed in 32.2% of patients. Capecitabine-attributed ST grade 1–3 was associated with a significantly higher disease control rate (DCR) (97.9 vs 86.1%, P=0.038) compared with grade 0 toxicity. Moreover, Cape-ST grade 1–3 related to a markedly longer progression-free survival (PFS) (9.9 vs 5.6 months, Pvs 22.4 months, P=0.008). Separate analyses of treatment arms indicated that the effect of Cape-ST on PFS remained significant for both arms, whereas the effect on OS remained apparent as a strong trend. This analysis supports the hypothesis that for the evaluated regimens, a correlation exists between Cape-ST and treatment efficacy regarding DCR, PFS, and OS.Keywords
This publication has 24 references indexed in Scilit:
- Potential Regional Differences for the Tolerability Profiles of FluoropyrimidinesJournal of Clinical Oncology, 2008
- Randomized Phase III Study of Capecitabine Plus Oxaliplatin Compared With Fluorouracil/Folinic Acid Plus Oxaliplatin As First-Line Therapy for Metastatic Colorectal CancerJournal of Clinical Oncology, 2008
- Adding cetuximab to capecitabine plus oxaliplatin (XELOX) in first-line treatment of metastatic colorectal cancer: a randomized phase II trial of the Swiss Group for Clinical Cancer Research SAKKAnnals of Oncology, 2008
- Phase III Study of Capecitabine Plus Oxaliplatin Compared With Continuous-Infusion Fluorouracil Plus Oxaliplatin As First-Line Therapy in Metastatic Colorectal Cancer: Final Report of the Spanish Cooperative Group for the Treatment of Digestive Tumors TrialJournal of Clinical Oncology, 2007
- Management of hand-foot syndrome induced by capecitabineJournal of Oncology Pharmacy Practice, 2006
- Hand‐Foot Syndrome in Patients Treated With Capecitabine‐Containing Combination ChemotherapyThe Journal of Clinical Pharmacology, 2004
- Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal CancerNew England Journal of Medicine, 2004
- Randomized multicenter Phase II trial of two different schedules of irinotecan combined with capecitabine as first‐line treatment in metastatic colorectal carcinomaCancer, 2004
- An Evolving Role for Oral Fluoropyrimidine DrugsJournal of Clinical Oncology, 2002
- Incidence and Severity of Hand–Foot Syndrome in Colorectal Cancer Patients Treated with Capecitabine: A Single-Institution ExperienceCancer Investigation, 2002